Proactive Investors - Run By Investors For Investors

IXICO unveils appointment of UK Biobank finance director Grant Nash as its chief financial officer

The AIM-listed neuroscience data analytics company said Grant will join the company on 29 April 2019 and it is anticipated that he will join the board in due course
Handshake
Prior to his time with the UK Biobank, Grant spent 10 years with Evotec AG, latterly as senior vice president of finance

IXICO PLC (LON:IXI) has announced the appointment of Grant Nash, currently finance director of the UK Biobank - a national and international health research data resource - as the company's chief financial officer.

The AIM-listed neuroscience data analytics company said Grant will join the company on 29 April 2019 and it is anticipated that he will join the board in due course.

READ: IXICO parts with director Susan Lowther

It added that Grant has been finance director of the UK Biobank since 2014, where he was also responsible for the UK Biocentre, which provides biomedical sample processing and archiving logistics to large-scale research studies.

Prior to his time with the UK Biobank, Grant spent 10 years with Evotec AG, latterly as senior vice president of finance, where he was responsible for the finance, IT, procurement facilities and logistics functions.

IXICO said Conor Woolfson, who assumed the role of interim head of finance in December 2018 after the departure of Susan Lowther, will continue to perform these duties prior to Grant's appointment, at which time he will then continue in his role of group financial controller, reporting to Grant.

Giulio Cerroni, IXICO’s chief executive said: "We are at an exciting stage of the Company's development, and Grant's business experience in international commercial and large-scale research and development organisations will assist the Board and management team in delivering against our strategic objectives."

View full IXI profile View Profile

IXICO PLC Timeline

Newswire
December 11 2018

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use